Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Gardasil / Gardasil 9 (HPV recombinant vaccine) by Year
Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. reported growth YoY (%) (%)
Merck Gardasil / Gardasil 9 (HPV recombinant vaccine): 9.0% in FY2025, down 7.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Gardasil/Gardasil 9 | 5,233 | 8,583 | -39 | 2,641 | 2,425 | 9 | 2,592 | 6,158 | -58”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Gardasil / Gardasil 9 (HPV recombinant vaccine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 9.0% | -7.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 16.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Merck Gardasil / Gardasil 9 (HPV recombinant vaccine) (%), annual FY2024–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-gardasil-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.